Welcome to our dedicated page for ARIDIS PHARMACEUTICAL news (Ticker: ARDS), a resource for investors and traders seeking the latest updates and insights on ARIDIS PHARMACEUTICAL stock.
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) is a biopharmaceutical company based in Los Gatos, California, focused on developing innovative anti-infective therapies for life-threatening infections. The company leverages its proprietary ʎPEX™ and MabIgX® technology platforms to identify potent B-cells from patients who have successfully overcome infections and rapidly manufacture monoclonal antibodies (mAbs) for therapeutic use. These mAbs are already of human origin and do not require further engineering optimization to achieve full functionality.
Aridis is advancing multiple clinical-stage mAbs targeting bacteria and viruses that cause severe infections such as ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP). The company’s novel approach addresses the limitations of current broad-spectrum antibiotics, such as increasing drug resistance, short duration of efficacy, and disruption of the human microbiome.
Highlighted in Aridis' pipeline are seven key products:
- AR-301 (VAP/HAP/CAP): A fully human IgG1 mAb targeting Staphylococcus aureus alpha-toxin, currently in Phase 3 clinical development.
- AR-320 (VAP): A fully human mAb for the prevention of VAP caused by S. aureus, in Phase 3 clinical development.
- AR-501 (Cystic Fibrosis): An inhaled formulation of gallium citrate to treat chronic lung infections in cystic fibrosis patients, in Phase 2a clinical study.
- AR-701 (COVID-19): A cocktail of fully human mAbs targeting SARS-CoV-2 spike proteins.
- AR-101 (HAP): A fully human IgM mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa liposaccharides serotype O11.
- AR-201 (RSV Infection): A fully human IgG1 mAb directed against the F-protein of respiratory syncytial virus (RSV), licensed to the Serum Institute of India.
- AR-401 (Blood Stream Infections): A preclinical mAb program targeting gram-negative Acinetobacter baumannii.
Aridis has recently achieved significant milestones including positive Phase 2a results for AR-501, FDA and EMA agreement on AR-301 Phase 3 study design, and multiple grants from the National Institute of Allergy and Infectious Diseases (NIAID). The company continues to explore strategic partnerships to advance its clinical programs and maximize value for shareholders.
Aridis Pharmaceuticals announced that its inhaled monoclonal antibody cocktail, AR-701, demonstrated significant effectiveness against SARS-CoV-2 Omicron subvariants in non-human primates. The treatment resulted in no detectable virus in the lungs and suppressed viral load in the nasal sinus and oropharynx over five days. This research, supported by various institutions and presented at a conference, marks a crucial milestone for AR-701, indicating potential for clinical success. The company aims to address ongoing COVID-19 challenges with accessible, long-acting therapies.
Aridis Pharmaceuticals (NASDAQ: ARDS) is featured in a new interview on The RedChip Money Report, airing on Bloomberg TV on July 2, 2022. The discussion led by CEO Vu Truong touches on upcoming clinical trial data expected in the second half of 2022. With price targets set between $11-$22 by five analysts, the company is positioned for potential stock appreciation. Their innovative platforms, ʎPEX and MabIgX®, enable rapid identification of monoclonal antibodies for treating infectious diseases, hinting at a shift in treatment paradigms.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced CEO Vu Truong will participate in a virtual fireside chat hosted by Maxim Group LLC and M-Vest on June 7, 2022, at 11 a.m. ET. The session will cover Aridis' late-stage development pipeline and data readout timelines. Investors can register for free via the webcast link provided. Aridis focuses on developing novel anti-infective therapies using proprietary technology to combat life-threatening infections and antimicrobial resistance.
Aridis Pharmaceuticals (Nasdaq: ARDS) reported Q1 2022 results with net loss of approximately $7.8 million or $0.44 per share, slightly improved from a net loss of $7.9 million or $0.77 per share in Q1 2021. The company is progressing in clinical trials for AR-501, AR-301, AR-320, and AR-701, with multiple data readouts expected in 2H 2022. Cash reserves stand at approximately $14.2 million post a $5 million non-dilutive loan. Revenues rose to $1.2 million, attributed to grants from notable foundations. Increased R&D expenses hit $6.5 million, reflecting ongoing development initiatives.
Aridis Pharmaceuticals (Nasdaq: ARDS) secured a $1.9 million grant from the Gates Foundation to advance inhaled monoclonal antibodies for influenza and COVID-19. The company reported a net loss of approximately $47.3 million for 2021, increasing from $22.3 million in 2020. Fourth-quarter gains included a rise in grant revenue to $1.5 million, supported by CF Foundation and Gates Foundation grants. Major clinical milestones are anticipated in 2022, including data readouts for AR-501 and AR-301, as well as initiating the AR-320 Phase 3 study.
On February 17, 2022, Aridis Pharmaceuticals (Nasdaq: ARDS) announced that its AR-701 monoclonal antibody cocktail effectively neutralized the SARS-CoV-2 Omicron variant in animal studies, providing complete protection against infection. The cocktail consists of two mAbs, AR-720 and AR-703, which exhibited broad efficacy against multiple Covid-19 variants. Additionally, the company received a $1.9 million grant from the Bill and Melinda Gates Foundation for further research on influenza and COVID-19 prevention. CEO Vu Truong affirmed AR-701's potential for long-term effectiveness against coronaviruses.
Aridis Pharmaceuticals (Nasdaq: ARDS) has received a $1.9 million grant from the Bill & Melinda Gates Foundation to develop inhaled monoclonal antibodies (mAbs) targeting influenza and SARS-CoV2, aimed at improving access in low- and middle-income countries. The mAbs will be manufactured using Lumen Bioscience's spirulina-based platform, which significantly reduces production costs. Aridis’ technology allows for self-administration of these antibodies, enhancing their bioavailability and effectiveness against respiratory viruses. This funding may extend to human clinical trials depending on preclinical outcomes.
Aridis Pharmaceuticals (Nasdaq: ARDS) announced that CEO Vu Truong discussed the company's monoclonal antibody cocktail, AR-701, on Fox Business. AR-701 targets coronavirus spike proteins and has shown effective neutralization against various SARS-CoV-2 variants, including Omicron. Animal studies indicate that AR-701 can provide long-lasting protection for up to a year. The product is being developed for both intramuscular and inhaled delivery methods to treat COVID-19 in non-hospitalized patients. The company aims to combat life-threatening infections through novel anti-infective therapies.
Aridis Pharmaceuticals (Nasdaq: ARDS) announced that its monoclonal antibody cocktail, AR-701, is effective against the Omicron variant and other COVID-19 variants, as well as SARS and MERS. AR-701 shows robust neutralization in vitro and demonstrates efficacy in animal models. Engineered for long-lasting action, it is expected to provide protection for up to one year. The mAb cocktail consists of AR-703 and AR-720, utilizing distinct mechanisms to enhance effectiveness against viral resistance. The development underscores Aridis' focus on innovative therapies for life-threatening infections.
Aridis Pharmaceuticals (Nasdaq: ARDS) reported Q3 2021 results, noting significant advancements in its clinical pipeline. The company in-licensed suvratoxumab (AR-320) from AstraZeneca, with a Phase 3 study set to launch in early 2022. Positive Phase 2 data indicated a 32% relative risk reduction in pneumonia. Financially, cash was approximately $18.2 million, with revenues of $0.4 million driven by a milestone payment for AR-501. However, R&D expenses surged to $19.8 million, primarily due to the AR-320 license agreement, resulting in a net loss of approximately $21.0 million.
FAQ
What is the current stock price of ARIDIS PHARMACEUTICAL (ARDS)?
What is the market cap of ARIDIS PHARMACEUTICAL (ARDS)?
What is Aridis Pharmaceuticals, Inc. known for?
What are the key products in Aridis' pipeline?
What technology platforms does Aridis use?
What recent achievements has Aridis Pharmaceuticals accomplished?
What is the focus of Aridis' clinical programs?
Where is Aridis Pharmaceuticals located?
How does Aridis Pharmaceuticals address antimicrobial resistance?
What are the strategic goals of Aridis Pharmaceuticals?
Who are the collaborators and partners of Aridis Pharmaceuticals?
What is AR-301 and what infections does it target?
